344 related articles for article (PubMed ID: 16403830)
1. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations.
Massara A; Cavazzini PL; Trotta F
Rheumatology (Oxford); 2006 Jun; 45(6):730-3. PubMed ID: 16403830
[TBL] [Abstract][Full Text] [Related]
2. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature.
Moll C; Hernández MV; Cañete JD; Gómez-Puerta JA; Soriano A; Collado A; Sanmartí R
Semin Arthritis Rheum; 2008 Apr; 37(5):299-306. PubMed ID: 17976692
[TBL] [Abstract][Full Text] [Related]
3. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients.
Amital H; Applbaum YH; Aamar S; Daniel N; Rubinow A
Rheumatology (Oxford); 2004 May; 43(5):658-61. PubMed ID: 14983108
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha blockers in SAPHO syndrome.
Ben Abdelghani K; Dran DG; Gottenberg JE; Morel J; Sibilia J; Combe B
J Rheumatol; 2010 Aug; 37(8):1699-704. PubMed ID: 20472920
[TBL] [Abstract][Full Text] [Related]
5. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab.
Iqbal M; Kolodney MS
J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S118-20. PubMed ID: 15858507
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome.
Hurtado-Nedelec M; Chollet-Martin S; Nicaise-Roland P; Grootenboer-Mignot S; Ruimy R; Meyer O; Hayem G
Rheumatology (Oxford); 2008 Aug; 47(8):1160-7. PubMed ID: 18559374
[TBL] [Abstract][Full Text] [Related]
7. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?
Roux CH; Brocq O; Leccia N; Giacchero D; Breuil V; Albert C; Lacour J; Perrin C; Euller-Ziegler L
J Rheumatol; 2007 Feb; 34(2):434-7. PubMed ID: 17295430
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
9. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate.
De Souza A; Solomon GE; Strober BE
Bull NYU Hosp Jt Dis; 2011; 69(2):185-7. PubMed ID: 22035400
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of severe SAPHO syndrome with adalimumab: case report and a review of the literature.
Garcovich S; Amelia R; Magarelli N; Valenza V; Amerio P
Am J Clin Dermatol; 2012 Feb; 13(1):55-9. PubMed ID: 22007948
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
12. Chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with associated neutrophilic dermatoses: a report of seven cases and review of the literature.
Tlougan BE; Podjasek JO; O'Haver J; Cordova KB; Nguyen XH; Tee R; Pinckard-Hansen KC; Hansen RC
Pediatr Dermatol; 2009; 26(5):497-505. PubMed ID: 19840301
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
14. SAPHO syndrome: misdiagnosed and operated.
Karadag-Saygi E; Gunduz OH; Gumrukcu G; Akyuz G
Acta Reumatol Port; 2008; 33(4):460-3. PubMed ID: 19078862
[TBL] [Abstract][Full Text] [Related]
15. Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism.
Sabugo F; Liberman C; Niedmann JP; Soto L; Cuchacovich M
Clin Rheumatol; 2008 Apr; 27(4):533-5. PubMed ID: 17938987
[TBL] [Abstract][Full Text] [Related]
16. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate.
Galadari H; Bishop AG; Venna SS; Sultan E; Do D; Zeltser R
J Am Acad Dermatol; 2009 Jul; 61(1):123-5. PubMed ID: 19539848
[TBL] [Abstract][Full Text] [Related]
17. [Diffuse sclerosing osteomyelitis of the mandible and SAPHO syndrome].
Fleuridas G; Teysseres N; Ragot JP; Chikhani L; Favre-Dauvergne E
Rev Stomatol Chir Maxillofac; 2002 Apr; 103(2):96-104. PubMed ID: 11997737
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of SAPHO syndrome with zoledronic acid.
Kopterides P; Pikazis D; Koufos C
Arthritis Rheum; 2004 Sep; 50(9):2970-3. PubMed ID: 15457466
[TBL] [Abstract][Full Text] [Related]
20. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
